# US 2014/0154309 A1 · Solid ganaxolone compositions and methods for the making and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154309 A1
- Document ID: US20140154309A1
- Status: Published application
- Kind: A1
- Application number: 14/087,903
- Filed: 2013-11-22
- Published: 2014-06-05
- Earliest claimed: 2005-11-28
- Assignees: Marinus Pharmaceuticals
- Applicants: Marinus Pharmaceuticals
- Inventors: Kenneth Shaw; Mingbao Zhang
- Web page: https://patentgrep.com/patent/US20140154309A1

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/143: {with inorganic compounds}
- A61K 9/145: {with organic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 9/5078: {with drug-free core}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 47/02: Inorganic compounds
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/20: Hypnotics; Sedatives
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S 977/775: Nanosized powder or flake, e.g. nanosized catalyst
- Y10S 977/906: Drug delivery
- Y10S 977/915: Therapeutic or pharmaceutical composition
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.

## Claims

### Claim at position 1

1-52. (canceled)

### Claim 53

A pharmaceutical composition comprising solid stabilized particles comprising ganaxolone, a hydrophilic polymer, a wetting agent, and an effective amount of a complexing agent which is a small organic molecule having a molecular weight less than 550 and containing a moiety selected from the group consisting of a phenol moiety, an aromatic ester moiety and an aromatic acid moiety, wherein the stabilized particles have a volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm, the complexing agent being present in an amount from about 0.05% to about 5% w/w, based on the weight particles of the solid; the pharmaceutical composition further comprising one or more pharmaceutically acceptable additives selected from the group consisting of a diluent, a binder, a disintegrant, a plasticizer, a stabilizer, and mixtures of any of the foregoing, the pharmaceutical composition being an oral solid dosage form.

### Claim 54 (depends on 53)

The pharmaceutical composition solid stabilized particles of claim 53, wherein the hydrophilic polymer is in an amount from about 3% to about 50%, w/w, based on the weight of the solid particles.

### Claim 55 (depends on 54)

The pharmaceutical composition solid stabilized particles of claim 54, wherein the wetting agent is in an amount from about 0.01% to about 10%, w/w, based on the weight of the solid particles.

### Claim 56 (depends on 53)

The pharmaceutical composition solid stabilized particles of claim 53, wherein the stabilized particles exhibit an increase in volume weighted median diameter (D50) of not more than about 150% when the particles are dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) at a concentration of 0.5 to 1 mg ganaxolone/mL and placed in a heated bath at 36° to 38° C. for 1 hour as compared to the D50 of the stabilized particles when the particles are dispersed in distilled water under the same conditions, wherein the volume weighted median diameter (D50) of the stabilized particles dispersed in SGF or SIF is less than about 750 nm.

### Claim 57 (depends on 53)

The pharmaceutical composition solid stabilized particles of claim 53, wherein the ganaxolone is in an amount from about 10% to about 80% based on the weight of the stabilized particles.

### Claim 58 (depends on 57)

The pharmaceutical composition solid stabilized particles of claim 57, wherein the ganaxolone is present in an amount from about 50% to about 80%, based on the weight of the particles.

### Claim 59 (depends on 57)

The pharmaceutical composition solid stabilized particles of claim 57, wherein the complexing agent is selected from the group consisting of one or more parabens, benzoic acid, phenol, methyl anthranilate, pharmaceutically acceptable salts thereof, and mixtures of any of the foregoing.

### Claim 60 (depends on 59)

The pharmaceutical composition of claim 59, wherein the complexing agent is one or more parabens or a pharmaceutically acceptable salt thereof.

### Claim 61 (depends on 59)

The pharmaceutical composition of claim 59, wherein the complexing agent is benzoic acid or a pharmaceutically acceptable salt thereof.

### Claim 62 (depends on 53)

The pharmaceutical composition of claim 53, wherein the complexing agent is methyl anthranilate.

### Claim 63 (depends on 53)

The pharmaceutical composition of claim 53, wherein the complexing agent is phenol.

### Claim 64 (depends on 60)

The pharmaceutical composition solid stabilized particles of claim 60, wherein the paraben is selected from the group consisting of methylparaben, ethylparaben, propylparaben, pharmaceutically acceptable salts thereof and mixtures thereof.

### Claim 65 (depends on 53)

The pharmaceutical composition solid stabilized particles of claim 53, wherein the hydrophilic polymer is selected from the group consisting of a cellulosic polymer, a vinyl polymer and mixtures thereof.

### Claim 66 (depends on 65)

The pharmaceutical composition solid stabilized particles of claim 65, wherein the cellulosic polymer is a cellulose ether.

### Claim 67 (depends on 66)

The pharmaceutical composition solid stabilized particles of claim 66, wherein the cellulose ether is hydroxypropylmethylcellulose.

### Claim 68 (depends on 65)

The pharmaceutical composition solid stabilized particles of claim 65, wherein the vinyl polymer is polyvinyl alcohol.

### Claim 69 (depends on 68)

The pharmaceutical composition solid stabilized particles of claim 68, wherein the vinyl polymer is vinyl pyrrolidone/vinyl acetate copolymer (S630).

### Claim 70 (depends on 4)

The pharmaceutical composition solid stabilized particles of claim 4, wherein the wetting agent is selected from the group consisting of sodium lauryl sulfate, a pharmaceutically acceptable salt of docusate, and mixtures thereof.

### Claim 71 (depends on 59)

The pharmaceutical composition of claim 59, further comprising an ionic dispersion modulator in an amount from about 1% to about 50%, w/w, based on the weight of the solid particles, and is an inorganic salt is selected from the group consisting of a magnesium salt, a calcium salt, a lithium salt, a potassium salt, a sodium salt and mixtures thereof, or an organic salt selected from the group consisting of a citrate salt, a succinate salt, a fumarate salt, a malate salt, maleate salt, a tartrate salt, a glutarate salt, a lactate salt and mixtures thereof.

### Claim 72 (depends on 59)

The pharmaceutical composition of claim 59, further comprising a an effective amount of a controlled release material such that the dosage form provides a therapeutic effect for about 8 to about 24 hours after administration.

### Claim 73 (depends on 72)

The pharmaceutical composition of claim 72, which is an oral solid dosage form comprising (i) a controlled release component comprising a first portion of said solid stabilized ganaxolone particles; and a controlled release material, and (ii) an immediate release component comprising a second portion of said solid stabilized ganaxolone particles.

### Claim 74 (depends on 72)

The pharmaceutical composition of claim 72, wherein the controlled release component is in the form of (i) a plurality of pharmaceutically acceptable beads coated with the first portion of said solid stabilized ganaxolone particles and overcoated with the controlled release material, or (ii) a plurality of matrices comprising the first portion of said solid stabilized ganaxolone particles dispersed in the controlled release material, or (iii) a tablet comprising the first portion of ganaxolone particles dispersed in a controlled release material, or (iv) a granulation comprising the first portion of ganaxolone particles and the controlled release material.

### Claim 75 (depends on 72)

The pharmaceutical composition of claim 72, wherein the controlled release component is a tablet and the immediate release component is coated onto the tablet.

### Claim 76 (depends on 59)

The pharmaceutical composition of claim 59, wherein the stable ganaxolone particles are in a form selected from crystalline form, amorphous form, semi-crystalline form, semi-amorphous form, and mixtures thereof.

### Claim 77 (depends on 72)

The pharmaceutical composition of claim 72, further comprising a pH dependent polymer, the pharmaceutical composition providing a delayed release of the ganaxolone from a time period from about 2 to about 12 hours after administration.

### Claim 78 (depends on 57)

The pharmaceutical composition of claim 57, wherein the pharmaceutical composition is a compressed tablet.

### Claim 79 (depends on 72)

The pharmaceutical composition of claim 72, wherein the pharmaceutical composition is a compressed tablet.

### Claim 80 (depends on 57)

The pharmaceutical composition of claim 57, wherein the pharmaceutical composition is contained inside a capsule.

### Claim 81 (depends on 74)

The pharmaceutical composition of claim 74, wherein the pharmaceutical composition is contained inside a capsule.

### Claim 82 (depends on 57)

The pharmaceutical composition of claim 57, incorporated into a tablet or capsule, wherein the dosage form provides a ratio of mean blood plasma fed AUC(0-τ) to fasted AUC(0-τ) from about 1:1 to about 4:1.

### Claim 83 (depends on 57)

The pharmaceutical composition of claim 57, which provides a ratio of mean blood plasma fed Cmax to fasted Cmax from about 1.5:1 to about 7:1.

### Claim 84 (depends on 82)

The pharmaceutical composition of claim 82, wherein the particles have a volume weighted median diameter (D50) from about 50 nm to about 1000 nm, and the dosage form provides a mean blood plasma AUC 0-24 hours from about 100 to about 375 ng*h/ml when a dose of 200 mg to 500 mg of the ganaxolone is orally administered to adult subjects in the fasted state.

### Claim 85 (depends on 57)

The pharmaceutical composition of claim 57, which provides a mean blood plasma Cmax from about 25 to about 70 ng/ml when a dose of 200 mg to 500 mg of the ganaxolone is orally administered to adult subjects in the fasted state.

### Claim 86 (depends on 82)

The pharmaceutical composition of claim 82, which provides a mean blood plasma AUC (0-48) hours from about 400 to about 1200 ng*h/ml when a dose of 200 mg to 500 mg of the ganaxolone is orally administered to adult subjects in the fed state.

### Claim 87 (depends on 57)

The pharmaceutical composition of claim 57, which provides a mean blood plasma Cmax from about 60 to about 250 ng/ml when a dose of 200 mg to 500 mg of the ganaxolone is orally administered to adult subjects in the fed state.

### Claim 88 (depends on 57)

The pharmaceutical composition of claim 57, which provides a mean blood plasma Cmax/Cmin ratio of not greater than about 4 to 1 at steady state with a dose of 200 to 500 mg ganaxolone to adult subjects in the fed or fasted state.

### Claim 89

A pharmaceutical composition comprising solid stabilized particles comprising ganaxolone, a hydrophilic polymer, a wetting agent, and an effective amount of a complexing agent selected from the group consisting of methyl paraben, propyl paraben, and mixtures thereof and being present in an amount from about 0.05% to about 5% w/w based on the weight particles of the solid; the pharmaceutical composition further comprising one or more pharmaceutically acceptable additives selected from the group consisting of a diluent, a binder, a disintegrant, a plasticizer, a stabilizer, and mixtures of any of the foregoing, wherein the stabilized particles have a volume weighted median diameter (D50) of the particles from about 50 nm to about 500 nm, the pharmaceutical composition being an oral solid dosage form and including from about 50 mg to about 800 mg ganaxolone.

### Claim 90 (depends on 89)

The pharmaceutical composition of claim 89, wherein the solid dosage form is an immediate release dosage form.

### Claim 91 (depends on 89)

The pharmaceutical composition of claim 89, further comprising a an effective amount of a controlled release material such that the dosage form provides a therapeutic effect for about 8 to about 24 hours after administration.

### Claim 92 (depends on 89)

The pharmaceutical composition of claim 89, which is an oral solid dosage form comprising (i) a controlled release component comprising a first portion of said solid stabilized ganaxolone particles; and a controlled release material, and (ii) an immediate release component comprising a second portion of said solid stabilized ganaxolone particles.

### Claim 93 (depends on 89)

The pharmaceutical composition of claim 89, wherein the controlled release component is in the form of (i) a plurality of pharmaceutically acceptable beads coated with the first portion of said solid stabilized ganaxolone particles and overcoated with the controlled release material, or (ii) a plurality of matrices comprising the first portion of said solid stabilized ganaxolone particles dispersed in the controlled release material, or (iii) a tablet comprising the first portion of ganaxolone particles dispersed in a controlled release material, or (iv) a granulation comprising the first portion of ganaxolone particles and the controlled release material.

### Claim 94 (depends on 93)

The pharmaceutical composition of claim 93, wherein the pharmaceutical composition is contained inside a capsule.

### Claim 95 (depends on 91)

The pharmaceutical composition of claim 91, wherein the pharmaceutical composition is a compressed tablet.

### Claim 96

A pharmaceutical composition comprising solid stabilized particles comprising ganaxolone, a hydrophilic polymer, a wetting agent, and an effective amount of a complexing agent selected from the group of small organic molecules having a molecular weight less than 550 and containing a moiety selected from the group consisting of a phenol moiety, an aromatic ester moiety and an aromatic acid moiety; the pharmaceutical composition further comprising one or more pharmaceutically acceptable additives selected from the group consisting of a diluent, a binder, a disintegrant, a plasticizer, a stabilizer, and mixtures of any of the foregoing, the stabilized particles having a volume weighted median diameter (D50) of the particles from about 50 nm to about 500 nm, the concentration of ganaxolone in the solid stabilized particles being at least 50% by weight and the composition including from about 50 mg to about 800 mg ganaxolone, wherein the pharmaceutical composition is an oral solid dosage form.

### Claim 97 (depends on 96)

The pharmaceutical composition of claim 96, wherein the complexing agent is selected from the group consisting of parabens, benzoic acid, methyl anthranilate, and pharmaceutically acceptable salts thereof and mixtures thereof.

### Claim 98 (depends on 96)

The pharmaceutical composition of claim 96, wherein the ganaxolone is present in an amount greater than 50% to about 80%, based on the weight of the particles.

### Claim 99 (depends on 96)

The pharmaceutical composition of claim 96, wherein the particles are incorporated into a dosage form selected from the group consisting of a tablet or capsule.
